Elevation Oncology Valuation
| ELEV Stock | USD 0.67 0.05 8.06% |
Elevation Oncology is undervalued. Elevation Oncology shows a prevailing Real Value of $2.22 per share. The current price of the firm is $0.67. Our model computes the value of Elevation Oncology from reviewing the firm fundamentals such as Shares Owned By Insiders of 0.26 %, shares owned by institutions of 83.89 %, and Current Valuation of (32.64 M) as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Elevation Oncology's valuation include:
Undervalued
Today
Please note that Elevation Oncology's price fluctuation is dangerous at this time. Calculation of the real value of Elevation Oncology is based on 3 months time horizon. Increasing Elevation Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Elevation stock is determined by what a typical buyer is willing to pay for full or partial control of Elevation Oncology. Since Elevation Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Elevation Stock. However, Elevation Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.67 | Real 2.22 | Target 7.0 | Hype 0.62 | Naive 0.59 |
The intrinsic value of Elevation Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Elevation Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Elevation Oncology helps investors to forecast how Elevation stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Elevation Oncology more accurately as focusing exclusively on Elevation Oncology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Elevation Oncology's intrinsic value based on its ongoing forecasts of Elevation Oncology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Elevation Oncology's closest peers.
Elevation Oncology Cash |
|
Elevation Valuation Trend
Analysing the historical paterns of Elevation Oncology's enterprise value and its market capitalization is a good way to estimate and gauge the value of Elevation Oncology over time and is usually enough for investors to make rational market timing decisions.
Elevation Oncology Total Value Analysis
Elevation Oncology is currently forecasted to have valuation of (32.64 M) with market capitalization of 39.41 M, debt of 30.14 M, and cash on hands of 122.54 M. The negative valuation of Elevation Oncology may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Elevation Oncology fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(32.64 M) | 39.41 M | 30.14 M | 122.54 M |
Elevation Oncology Asset Utilization
One of the ways to look at asset utilization of Elevation is to check how much profit was generated for every dollar of assets it reports. Elevation Oncology shows a negative utilization of assets of -0.25 percent, losing $0.002546 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Elevation Oncology shows how discouraging it operates for each dollar spent on its assets.Elevation Oncology Ownership Allocation
Elevation Oncology holds a total of 59.12 Million outstanding shares. The majority of Elevation Oncology outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Elevation Oncology to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Elevation Oncology. Please pay attention to any change in the institutional holdings of Elevation Oncology as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Elevation Oncology Profitability Analysis
Net Loss for the year was (45.7 M) with profit before overhead, payroll, taxes, and interest of 0.About Elevation Oncology Valuation
Our relative valuation model uses a comparative analysis of Elevation Oncology. We calculate exposure to Elevation Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Elevation Oncology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -35.1 K | -36.9 K |
Elevation Oncology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Elevation Oncology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 34.1 M |
Elevation Oncology Current Valuation Indicators
Elevation Oncology's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Elevation Oncology's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Elevation Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Elevation Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Elevation Oncology's worth.Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.